1. Ahmed, Z., Fraser, W., Kerr, M. P., Kiernan, C., Emerson, E., Robertson, J., …, Thomas, J. (2000). Reducing antipsychotic medication in people with a learning disability. British Journal of Psychiatry, 176, 42–46.
2. Aman, M. G., De Smedt, G., Derivan, A., Lyons, B., & Findling, R. L. (2002). The Risperidone Disruptive Behavior Study Group: Risperidone treatment of children with disruptive behavior disorders and subaverage IQ: A double-blind, placebo-controlled study. American Journal of Psychiatry, 159, 1337–1346.
3. Aman, M. G., Sarpharc, G., & Burrow, W. H. (1995). Psychotropic drugs in group homes: Prevalence and relation to demographic and psychiatric variables. American Journal on Mental Retardation, 99, 500–509.
4. Aman, M. G., & Singh, N. N. (1982). Methylphenidate in severely retarded residents and the clinical significance of stereotypic behavior. Applied Research in Mental Retardation, 3(4), 345–358.
5. Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89, 485–491.